Sobol Żaneta, Chiczewski Rafał, Wątróbska-Świetlikowska Dorota
Department of Pharmaceutical Technology, Pomeranian Medical University in Szczecin, Rybacka 1, 70-204 Szczecin, Poland.
Pharmaceutics. 2025 Jul 5;17(7):885. doi: 10.3390/pharmaceutics17070885.
Liposomes represent a cornerstone of modern drug delivery systems due to their unique structural and physicochemical characteristics. Extensive research has refined their formulation, stability, and targeting capabilities, leading to numerous clinical applications, particularly in oncology. A key clinical feature is their ability to accumulate in malignant tissues via the enhanced permeability and retention effect, offering improved pharmacokinetics and reduced systemic toxicity. Advances in liposomal engineering, including PEGylation and ligand-based targeting, have significantly enhanced pharmacokinetic profiles and tissue specificity, minimizing off-target toxicity. The modern approach to nanocarrier-based drugs offers multidirectional perspectives on targeted therapy. Liposomes can bypass drug resistance mechanisms and provide controlled or stimuli-responsive drug release. Current trends in liposome research focus on hybrid nanocarriers, personalized medicine applications, and combination therapies.
由于其独特的结构和物理化学特性,脂质体是现代药物递送系统的基石。广泛的研究优化了它们的配方、稳定性和靶向能力,从而带来了众多临床应用,尤其是在肿瘤学领域。一个关键的临床特性是它们能够通过增强的渗透和滞留效应在恶性组织中积累,从而改善药代动力学并降低全身毒性。脂质体工程的进展,包括聚乙二醇化和基于配体的靶向,显著增强了药代动力学特征和组织特异性,将脱靶毒性降至最低。基于纳米载体的药物的现代方法为靶向治疗提供了多方向的视角。脂质体可以绕过耐药机制,并提供可控或刺激响应性药物释放。脂质体研究的当前趋势集中在混合纳米载体、个性化医学应用和联合疗法上。